341
Participants
Start Date
November 30, 2010
Primary Completion Date
April 30, 2012
Study Completion Date
April 30, 2012
LCZ696
Participants received LCZ696 200 mg as the starting dose with optional down titration to 100 mg for tolerance and optional up titration to 400 mg for adequate blood pressure control.
Amlodipine
Optional add-on of amlodipine (5-10 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
Hydrochlorothiazide (HCTZ)
Optional add-on of hydrochlorothiazide (HCTZ) (12.5-25 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
Novartis Investigative Site, Taipei
Novartis Investigative Site, Changhua
Novartis Investigative Site, Taipei
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Taipei
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Taichung
Novartis Investigative Site, Chiang Mai
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Hangzhou
Novartis Investigative Site, Chongqing
Novartis Investigative Site, Shijiazhuang
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Shimotsuke
Novartis Investigative Site, Bunkyo-ku
Novartis Investigative Site, Chiyoda-ku
Novartis Investigative Site, Kiyose
Novartis Investigative Site, Kunitachi
Novartis Investigative Site, Minato-ku
Novartis Investigative Site, Minato-ku
Novartis Investigative Site, Ōta-ku
Novartis Investigative Site, Shinagawa-ku
Novartis Investigative Site, Shinagawa-ku
Novartis Investigative Site, Shinagawa-ku
Novartis Investigative Site, Toshima-ku
Novartis Investigative Site, Bucheon-si
Novartis Investigative Site, Seoul
Novartis Investigative Site, Koyang
Novartis Investigative Site, Daegu
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY